ITM2B

Across TCGA pan-cancer cohorts, ITM2B mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ITM2B data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ITM2B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ITM2B expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, UCEC, and OV are the cancer types where ITM2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.638	0.845	.003	53	view →
UCEC	OS	Median	III,IV	0.311	1.000	.001	40	view →
OV	DFS	Tertile	All	0.547	1.000	.016	16	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
CCRCC	DFS	Median	III,IV	0.526	0.809	.035	3	view →
PDAC	OS	Median	III,IV	0.537	1.000	.008	3	view →
LSCC	DFS	Median	III,IV	0.944	0.648	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ITM2B–LUAD (DFS)

Open the LUAD breakdown →